Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells

Cell Cycle

Volumn 10, Issue 1, 2011, Pages 100-107

  Nowicki, Theodore S ^a   Zhao, Hong ^a   Darzynkiewicz, Zbigniew ^a   Moscatello, Augustine ^a   Shin, Edward ^a   Schantz, Stimson ^a   Tiwari, Raj K ^a   Geliebter, Jan ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

And akt; FAK; Invasion; Migration; Papillary thyroid carcinoma; PI3K; Proliferation; Senescence; Urokinase plasminogen activator receptor (uPAR)

Indexed keywords

BETA GALACTOSIDASE; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN; PROTEIN KINASE B; SMALL INTERFERING RNA; UROKINASE RECEPTOR;

ARTICLE; BETA RHYTHM; CANCER INVASION; CARCINOGENESIS; CARCINOMA CELL; CELL MIGRATION; CLONOGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FOCAL ADHESION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; METASTASIS; MORPHOLOGY; PAPILLARY CARCINOMA; PLASMINOGEN ACTIVATION; RECEPTOR DOWN REGULATION; SENESCENCE; SIGNAL TRANSDUCTION; THYROID CARCINOMA;

EID: 78650801365     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.1.14362     Document Type: Article

References (39)

1. Wartofsky L. Increasing world incidence of thyroid cancer: increased detection or higher radiation exposure? Hormones (Athens) 2010; 9:103-8; PMID: 20687393.
2. Roh JL, Park JY, Park CI. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients. Ann Surg 2007; 245:604-10; PMID: 17414610; DOI: 10.1097/01.sla.0000250451.59685.67.
3. Lee YS, Lim YS, Lee JC, Wang SG, Kim IJ, Lee BJ. Clinical implication of the number of central lymph node metastasis in papillary thyroid carcinoma: preliminary report. World J Surg 2010; 34:2558-63; PMID: 20703463; DOI: 10.1007/s00268-010-0749-0.
4. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338:297-306; PMID: 9445411.
5. Fagin JA, Tuttle RM, Pfister DG. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2621-4; PMID: 20525911; DOI: 20525911.
6. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, et al. Secondary primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89:1638-44; PMID: 12973856; DOI:10.1038/sj.bjc.6601319.
7. Smith HW, Marshall CJ. Regulation of cell signaling by uPAR. Nat Rev Mol Cell Bio 2010; 11:23-36; PMID: 20027185; DOI: 10.1038/nrm2821.
8. Gondi CS, Rao JS. Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor and matrix metalloproteinases. Methods Mol Biol 2009; 487:267-81; PMID: 19301652.
9. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003; 22:4578-80; PMID: 12881714; DOI: 10.1038/sj.onc.1206706.
10. Lengyel E, Wang H, Stepp E, Juarez J, Wang Y, Doe W, et al. Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J Biol Chem 1996; 271:23176-84; PMID: 8798512; DOI: 10.1074/jbc.271.38.23176.
11. Bessard A, Frémin C, Ezan F, Coutant A, Baffet G. MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells. J Cell Physiol 2007; 212:526-36; PMID: 17427199; DOI: 10.1002/jcp.21049.
12. Ulisse S, Baldini E, Toller M, Marchioni E, Giacomelli L, De Antoni E, et al. Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. Eur J Cancer 2006; 42:2631-8; PMID: 16928445; DOI: 10.1016/j.ejca.2006.04.017.
13. Nowicki TS, Kummer NT, Iacob C, Suslina N, Schaefer S, Schantz S, et al. Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells. Laryngoscope 2010; 120:1383-90; PMID: 20578104; DOI: 10.1002/lary.20915.
14. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 1994; 14:1680-8; PMID: 7509446.
15. Chen HC, Appeddu PA, Isoda H, Guan JL. Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol-3-kinase. J Biol Chem 1996; 271:26329-34; PMID: 8824286; DOI: 10.1074/jbc.271.42.26329.
16. Zhao H, Halicka HD, Traganos F, Jorgensen E, Darzynkiewicz Z. New biomarkers probing the depth of cell senescence assessed by laser scanning cytometry. Cytometry Part A 2010; 77:999-1007; PMID: 20939035; DOI: 10.1002/cyto.a.20983.
17. Itahana K, Campisi J, Dimri GP. Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. Methods Mol Biol 2007; 371:21-31; PMID: 17634571.
18. V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: Analysis of 1,060 Cases. J Clin Endocrinol Metab 2010; 95:4197-205; PMID: 20631031; DOI: 10.1210/jc.2010-0337.
19. 600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 2006; 66:6521-9; PMID: 16818623; DOI: 10.1158/0008-5472.can-06-0739.
20. Nguyen T, Menocal EM, Harborth J, Fruehauf JH. RNAi therapeutics: An update on delivery. Curr Opin Mol Ther 2008; 10:158-67; PMID: 18386228.
21. Rye PD, Stigbrand T. Interfering with cancer: a brief outline of advances in RNA interference in oncology. Tumor Biol 2004; 25:329-36; PMID: 15627900.
22. Wilda M, Fuchs U, Wössmann W, Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 2002; 21:5716-24; PMID: 12173041; DOI: 10.1038/sj.onc.1205653.
23. Gondi CS, Kandhukuri N, Dinh DH, Gujrati M, Rao JS. Downregulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int J Oncol 2007; 31:19-27; PMID: 17549401.
24. Falasca M. PI3K/Akt signalling pathway specific inhibitors: A novel strategy to sensitize cancer cells to anticancer drugs. Curr Pharm Des 2010; 16:1410-6; PMID: 20166984.
25. Liang X, Yang X, Tang Y, Zhou H, Liu X, Xiao L, et al. RNAi-mediated downregulation of urokinase plasminogen activator receptor inhibits proliferation, adhesion, migration and invasion in oral cancer cells. Oral Oncol 2008; 44:1172-80; PMID: 18486529; DOI: 10.1016/j.oraloncology.2008.03.004.
26. Cristofali VJ, Pignolo RJ. Replicative senescence of human fibroblast-like cells in culture. Physiol Rev 1993; 78:617-25; PMID: 8332640.
27. Hwang ES, Yoon G, Kang HT. A comparative analysis of the cell biology of senescence and aging. Cell Mol Life Sci 2009; 66:2503-24; PMID: 19421842; DOI: 10.1007/s00018-009-0034-2.
28. Darzynkiewicz Z, Traganos F, Melamed MR. New cell cycle compartments identified by multiparameter flow cytometry. Cytometry 1980; 1:98-108; PMID: 6170495.
29. Traganos F, Darzynkiewicz Z, Sharpless T, Melamed MR. Erythroid differentiation of Friend leukemia cells as studies by acridine orange staining and flow cytometry. J Histochem Cytochem 1979; 27:382-9; PMID: 86567.
30. Pospelova TV, Demidenko ZN, Bukreeva EI, Pospelov VA, Gudkov AV, Blagosklonny MV. Pseudo-DNA damage response in senescent cells. Cell Cycle 2009; 8:4112-8; PMID: 19946210.
31. Darzynkiewicz Z. When senescence masquerades as DNA damage: is DNA replication stress the culprit? Cell Cycle 2009; 8:3810-1; PMID: 19887905.
32. Kip1. J Biol Chem 2000; 275:21960-8; PMID: 10791951; DOI: 10.1074/jbc.M000759200.
33. Axanova LS, Chen YQ, McCoy T, Sui G, Cramer SD. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells. Prostate 2010; 70:1658-71; PMID: 20583132; DOI: 10.1002/pros.21201.
34. Sumikawa E, Matsumoto Y, Sakemura R, Fujii M, Ayusawa D. Prolonged unbalanced growth induces cellular senescence markers linked with mechano transduction in normal and tumor cells. Biochem Biophys Res Commun 2005; 335:558-65; PMID: 16083852; DOI: 10.1016/j.bbrc.2005.07.106.
35. Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging 2010; 2:344-52; PMID: 20606252.
36. Demidenko ZN, Shtutman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle 2009; 8:1896-900; PMID: 19478560.
37. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle 2009; 8:1888-95; PMID: 19471117.
38. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436:720-4; PMID: 16079850; DOI: 10.1038/nature03890.
39. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006; 10:459-72; PMID: 17157787; DOI: 10.1016/j.ccr.2006.10.003.